Heron Therapeutics Inc HRTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")
-
Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer
-
Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance
-
Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024
-
Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System
-
Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")
-
Heron Therapeutics Shares Rise 15% After FDA Approves Expanded Use of Zynrelef
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.25
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 126
- Website
- https://www.herontx.com
Comparables
Valuation
|
Metric
|
HRTX
|
CRMD
|
SLRN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 9.63 | 0.86 |
Price/Sales | 2.25 | 572.38 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
HRTX
|
CRMD
|
SLRN
|
|---|---|---|---|
Quick Ratio | 1.76 | 4.12 | 7.77 |
Current Ratio | 2.38 | 4.79 | 7.86 |
Interest Coverage | — | −1,599.40 | — |
Quick Ratio
HRTX
CRMD
SLRN
Profitability
|
Metric
|
HRTX
|
CRMD
|
SLRN
|
|---|---|---|---|
Return on Assets (Normalized) | −11.68% | −66.44% | −31.90% |
Return on Equity (Normalized) | — | −77.20% | −34.95% |
Return on Invested Capital (Normalized) | −18.15% | −81.35% | −40.49% |
Return on Assets
HRTX
CRMD
SLRN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Ngqbmqvsd | Lkdw | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Jyjgsxb | Flwnw | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Tlzzxdtt | Bwrfb | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Fljsbrw | Btfrlc | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Hdqtfhfqb | Vpzpp | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Lgvnngv | Kqvwc | $28.1 Bil | |||
| Moderna Inc
MRNA
| Kghyhggl | Xqyll | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Hvdbclsg | Yhly | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Dmkkdqzz | Vmxwww | $13.4 Bil | |||
| Incyte Corp
INCY
| Dtxzrzykp | Xmjgl | $12.7 Bil |
United States